The asia pacific Fabry’s disease treatment market size is expected to reach USD 1,088.17 million by 2034, according to a new study by Polaris Market Research. The report “Asia Pacific Fabry’s Disease Treatment Market Size, Share, & Industry Analysis Report: By Route of Administration (Intravenous Route and Oral Route), By Therapy, By Distribution Channel, and By Country – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The Asia Pacific Fabry’s disease treatment market represents a rapidly evolving segment within the rare disease therapeutics landscape, driven by increased clinical awareness, expanding diagnostic infrastructure, and rising accessibility to advanced biologics. The market encompasses a range of therapeutic approaches aimed at managing lysosomal alpha-galactosidase A enzyme deficiency, which underpins the pathophysiology of Fabry’s disease. Accelerated efforts in early diagnosis through newborn screening programs and targeted genetic testing are supporting timely therapeutic intervention, improving long-term patient outcomes. Increasing pharmaceutical R&D activity focused on enzyme replacement therapy (ERT), substrate reduction therapy (SRT), and gene-based modalities is pushing the development pipeline forward.
Strategic pricing reforms and the inclusion of Fabry’s therapies in national rare disease programs are enabling broader treatment access. Additionally, the availability of oral formulations and home-infusion protocols is enhancing patient adherence and quality of life, driving sustained treatment uptake. A growing focus on developing next-generation recombinant enzymes and chaperone therapies tailored for Asian genetic variants is reinforcing innovation in this space. The increasing integration of real-world evidence (RWE) to support regulatory and reimbursement pathways reflects a maturing market outlook. Technological advances in digital health tools are enabling longitudinal monitoring and improved disease management.
Asia Pacific Fabry’s Disease Treatment Market Report Highlights
By route of administration, in 2024, the intravenous route segment accounted for the largest share. The dominance of this segment is attributed to the established use of enzyme replacement therapy (ERT), which is typically administered intravenously.
Based on therapy, in 2024, the enzyme replacement therapy (ERT) segment accounted for the largest share. This dominance is largely attributed to the extensive clinical evidence supporting ERT in managing both classic and atypical Fabry’s manifestations.
The China Fabry’s disease treatment market accounted for the largest share. This growth is driven by rising awareness among healthcare professionals and patients, improved diagnostic capabilities, and an increasing number of patients being identified and treated.
A few key players include Amicus Therapeutics, Inc.; CANbridge Life Sciences Ltd.; Chiesi Farmaceutici S.p.A.; Idorsia Pharmaceuticals Ltd.; ISU ABXIS Co., Ltd.; JCR Pharmaceuticals Co., Ltd.; Protalix Biotherapeutics Inc.; Sangamo Therapeutics, Inc.; Sanofi; and Takeda Pharmaceutical.
Polaris Market Research has segmented the Asia Pacific Fabry’s disease treatment market report on the basis of route of administration, therapy, distribution channel, and region:
By Route of Administration Outlook (Revenue, USD Million, 2020–2034)
Intravenous Route
Oral Route
By Therapy Outlook (Revenue, USD Million, 2020–2034)
Enzyme Replacement Therapy (ERT)
Substrate Reduction Therapy (SRT)
Others
By Distribution Channel Outlook (Revenue, USD Million, 2020–2034)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country Outlook (Revenue, USD Million, 2020–2034)
China
Japan
India
South Korea
Taiwan
Indonesia
Malaysia
Pakistan
Rest of Asia Pacific
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. Asia Pacific Fabry’s Disease Treatment Market Insights
- 4.1. Asia Pacific Fabry’s Disease Treatment Market – Market Snapshot
- 4.2. Asia Pacific Fabry’s Disease Treatment Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Pharmaceutical R&D Investments
- 4.2.1.2. Expansion of Medical Tourism
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Shortage of Skilled Personal
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Asia Pacific Fabry’s Disease Treatment Market Trends
- 4.6. Value Chain Analysis
- 5. Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 5.3. Intravenous Route
- 5.3.1. Asia Pacific Fabry’s Disease Treatment Market, by Intravenous Route, by Country, 2020-2034 (USD Million)
- 5.4. Oral Route
- 5.4.1. Asia Pacific Fabry’s Disease Treatment Market, by Oral Route, by Country, 2020-2034 (USD Million)
- 6. Asia Pacific Fabry’s Disease Treatment Market, by Therapy
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 6.3. Enzyme Replacement Therapy (ERT)
- 6.3.1. Asia Pacific Fabry’s Disease Treatment Market, by Enzyme Replacement Therapy (ERT), by Country, 2020-2034 (USD Million)
- 6.4. Substrate Reduction Therapy (SRT)
- 6.4.1. Asia Pacific Fabry’s Disease Treatment Market, by Substrate Reduction Therapy (SRT), by Country, 2020-2034 (USD Million)
- 6.5. Others
- 6.5.1. Asia Pacific Fabry’s Disease Treatment Market, by Others, by Country, 2020-2034 (USD Million)
- 7. Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.3. Hospital Pharmacies
- 7.3.1. Asia Pacific Fabry’s Disease Treatment Market, by Hospital Pharmacies, by Country, 2020-2034 (USD Million)
- 7.4. Retail Pharmacies
- 7.4.1. Asia Pacific Fabry’s Disease Treatment Market, by Retail Pharmacies, by Country, 2020-2034 (USD Million)
- 7.5. Online Pharmacies
- 7.5.1. Asia Pacific Fabry’s Disease Treatment Market, by Online Pharmacies, by Country, 2020-2034 (USD Million)
- 8. Asia Pacific Fabry’s Disease Treatment Market, by Country
- 8.1. Key Findings
- 8.2. Introduction
- 8.3. Asia Pacific Fabry’s Disease Treatment Market – Asia Pacific
- 8.3.1. Asia Pacific: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.3.2. Asia Pacific: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.3.3. Asia Pacific: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.4. Asia Pacific Fabry’s Disease Treatment Market – China
- 8.3.4.1. China: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.3.4.2. China: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.3.4.3. China: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.5. Asia Pacific Fabry’s Disease Treatment Market – India
- 8.3.5.1. India: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.3.5.2. India: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.3.5.3. India: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.6. Asia Pacific Fabry’s Disease Treatment Market – Malaysia
- 8.3.6.1. Malaysia: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.3.6.2. Malaysia: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.3.6.3. Malaysia: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.7. Asia Pacific Fabry’s Disease Treatment Market – Japan
- 8.3.7.1. Japan: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.3.7.2. Japan: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.3.7.3. Japan: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.8. Asia Pacific Fabry’s Disease Treatment Market – Indonesia
- 8.3.8.1. Indonesia: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.3.8.2. Indonesia: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.3.8.3. Indonesia: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.9. Asia Pacific Fabry’s Disease Treatment Market – South Korea
- 8.3.9.1. South Korea: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.3.9.2. South Korea: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.3.9.3. South Korea: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.10. Asia Pacific Fabry’s Disease Treatment Market – Australia
- 8.3.10.1. Australia: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.3.10.2. Australia: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.3.10.3. Australia: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.11. Asia Pacific Fabry’s Disease Treatment Market – Rest of Asia Pacific
- 8.3.11.1. Rest of Asia Pacific: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.3.11.2. Rest of Asia Pacific: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.3.11.3. Rest of Asia Pacific: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
- 10. Company Profiles
- 10.1. Amicus Therapeutics, Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. CANbridge Life Sciences Ltd.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Chiesi Farmaceutici S.p.A.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Idorsia Pharmaceuticals Ltd.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. ISU ABXIS Co., Ltd.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. JCR Pharmaceuticals Co., Ltd.
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Protalix Biotherapeutics Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Sangamo Therapeutics, Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Sanofi
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Takeda Pharmaceutical
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook